Hey Indy you seem like a bit of a troll to be honest - I went through your comment history and it appears you place a lot of negative comments just to provoke reaction.
First of all you have failed to understand where this stock currently sits - is it in development stage or is it in production stage where it is being evaluated on revenue? I will answer this question by noting NTI is currently being evaluated on development stage milestones - it's latest being the impending result of its double blind study. I might just add I have posted two references that indicate clinical success for neurofeedback in general as a proven science [1][2] with NTI's preliminary results also indicating success - full double blind study impending.
The fact that you embarrassed yourself a little by stating NTI will not double in price as it currently has no revenue stream is a little amateur as I specifically trade in development stage stocks with no revenue and all of them have gone up between 50% - 100%. This includes: CR8, NOR and WGL (last year). I will spell it out for you - a company does not require revenue to move their share price up in the development stage of their development.
NTI also has a potential market of 140,000 in Europe alone not even including the USA with a unit price of circa $2865. With no competitors in the 'in-home' market you look little silly by saying: "it will probably never have a revenue stream." Especially in consideration to the fact that NTI has no 'in-home' device competition.
I suggest if you wish to start a new thread in the future you do so with more than only 9 words.
I ask other traders on NTI do not respond to Indy he appears to be trolling this site. Remember do not feed the trolls.
References
[1] Trevisan, A and P, Cavallari. A Portable Sonified Neurofeedback Therapy for Autism Spectrum Disorder Patients - An Initial Evaluation. Journal of Neurological Disorders. AAT Research in conjuction with; University of California. USA. 2013.
[2] Jarusiewicz, B. Efficacy of Neurofeedback for Children in the Autistic Spectrum: A Pilot Study PhD. Pages 39-49. 2008
NTI Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
